Physician profile
Jyotsna Mullur
NPI 1861842023
$13,145.14
in general payments reported to CMS, 2019-2025
7 companies · $8,064 in 2025
The $8,064 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $5,082 · 2025: $8,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,516 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,504 · Food and Beverage: $1,058 · Travel and Lodging: $66.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,516.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,504.00 |
| Food and Beverage | $1,058.29 |
| Travel and Lodging | $66.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $9,159.65 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $3,198.00 | 2024 | Dupixent |
| Genentech USA, INC. | $406.85 | 2024-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $114.12 | 2024-2025 | Dupixent |
| Grifols Shared Services North America, INC. | $97.43 | 2025 | Xembify |
| Csl Behring | $90.52 | 2025 | Andembry |
| Glaxosmithkline, LLC. | $78.57 | 2024-2025 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyotsna Mullur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.